Share on StockTwits

OncoGenex Pharmaceuticals (NASDAQ:OGXI) was downgraded by investment analysts at RBC Capital from an “outperform” rating to a “sector perform” rating in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. They currently have a $4.50 target price on the stock, down from their previous target price of $19.00. RBC Capital’s price objective points to a potential upside of 14.80% from the stock’s previous close.

OGXI has been the subject of a number of other recent research reports. Analysts at Needham & Company LLC downgraded shares of OncoGenex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday. They now have a $14.00 price target on the stock, down previously from $30.00. Analysts at CRT Capital initiated coverage on shares of OncoGenex Pharmaceuticals in a research note on Thursday, February 27th. They set a “buy” rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $12.70.

Shares of OncoGenex Pharmaceuticals (NASDAQ:OGXI) traded up 1.82% on Tuesday, hitting $3.92. 1,439,080 shares of the company’s stock traded hands. OncoGenex Pharmaceuticals has a 52 week low of $3.82 and a 52 week high of $14.25. The stock has a 50-day moving average of $10.82 and a 200-day moving average of $9.59. The company’s market cap is $57.7 million.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.21. The company had revenue of $8.60 million for the quarter, compared to the consensus estimate of $10.20 million. Analysts expect that OncoGenex Pharmaceuticals will post $-1.33 EPS for the current fiscal year.

OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.